{"filings":[{"id":109877,"accession_number":"0001193125-26-134656","cik":1847903,"company_name":"Centessa Pharmaceuticals plc","ticker":"CNTA","form_type":"8-K","filed_at":"2026-03-31T23:59:59+00:00","items":["1.01","7.01","9.01"],"status":"ready","headline":"Eli Lilly to acquire Centessa for $38/share plus up to $9 in CVRs","event_type":"m_and_a","confidence":"high","bullets":["Centessa shareholders receive $38.00 per share cash plus CVRs worth up to $9.00 per share on milestone achievement.","CVR milestones: $2 for first US NDA of ORX750/ORX142 by Dec 31, 2029; $5 for IH approval within 5 yrs; $2 for NT2 approval within 5 yrs.","Supporting shareholders owning ~20% of shares agreed to vote in favor of the scheme.","Transaction expected to close by Sept 30, 2026, extendable to March 31, 2027 for HSR clearance.","Termination fee of ~$63M payable by Centessa under certain circumstances."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.95,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":109876,"accession_number":"0001193125-26-051424","cik":1847903,"company_name":"Centessa Pharmaceuticals plc","ticker":"CNTA","form_type":"8-K","filed_at":"2026-02-13T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Centessa finalizes advisory and separation pacts with former CEO Saha","event_type":"leadership","confidence":"high","bullets":["Saurabh Saha stepped down as CEO on Jan 1, 2026; advisory agreement signed Feb 9, 2026.","Advisory fee of $376/hour for initial six-month term, renewable automatically.","Separation provides vesting of equity through Feb 2, 2026; later equity forfeited.","Subject to Compensation Committee approval, Saha eligible for 100% of 2025 target bonus.","Vested equity exercise window extends to three months after advisory agreement ends."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":109875,"accession_number":"0001193125-26-004896","cik":1847903,"company_name":"Centessa Pharmaceuticals plc","ticker":"CNTA","form_type":"8-K/A","filed_at":"2026-01-07T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Centessa appoints Mario Accardi CEO effective Jan 1, 2026; base salary $600K, target bonus 50%","event_type":"leadership","confidence":"high","bullets":["Employment Agreement signed Jan 5, 2026; base salary $600,000 per year.","Target annual incentive bonus set at 50% of base salary, first eligible in 2027.","Termination without cause or for good reason (outside 1-yr post-sale): 12 months salary continuation.","Termination within 1 year post-sale event: lump sum of 18 months salary plus 150% target bonus.","Agreement supersedes prior Orexia Ltd employment contract from Jan 2019."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":126412,"accession_number":"0001193125-25-315074","cik":1847903,"company_name":"Centessa Pharmaceuticals plc","ticker":"CNTA","form_type":"8-K","filed_at":"2025-12-11T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Centessa appoints Mario Accardi as CEO; Saurabh Saha steps down effective Jan 1, 2026","event_type":"leadership","confidence":"high","bullets":["Mario Accardi, President of Orexin Program, becomes CEO on Jan 1, 2026; Saha becomes advisor.","Accardi's base salary set at $600k, target bonus 50%, equity awards target $6M.","Company focuses on orexin franchise; ORX750 registrational program expected to start Q1 2026.","Accardi founded Orexia (acquired by Centessa in 2021) and raised €40M Series A.","Saha resignation not due to any disagreement with company's operations or policies."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":126411,"accession_number":"0001193125-25-292015","cik":1847903,"company_name":"Centessa Pharmaceuticals plc","ticker":"CNTA","form_type":"8-K","filed_at":"2025-11-24T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Centessa Pharma enters into $250M ATM equity offering facility with Leerink Partners","event_type":"other_material","confidence":"high","bullets":["Up to $250M of American Depositary Shares may be sold through Leerink as sales agent.","Commission of 3.0% on gross proceeds; Leerink also receives up to $150K legal expense reimbursement.","No minimum offering amount; net proceeds expected for working capital, capex, and general corporate purposes.","Amends and restates prior sales agreement dated January 27, 2023, with Leerink."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":126410,"accession_number":"0001193125-25-278827","cik":1847903,"company_name":"Centessa Pharmaceuticals plc","ticker":"CNTA","form_type":"8-K","filed_at":"2025-11-13T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"Centessa prices $250M public offering of 11.6M ADSs at $21.50 per ADS","event_type":"other_material","confidence":"high","bullets":["Priced 11,627,907 ADSs at $21.50 each; gross proceeds ~$250M; net proceeds ~$234.4M.","Underwriters granted 30-day option to purchase up to 1,744,186 additional ADSs.","Offering expected to close November 14, 2025; proceeds to fund product development and general corporate purposes.","Existing cash plus net proceeds expected to fund operating expenses into 2028.","Jefferies, Leerink Partners, Evercore ISI, and Guggenheim Securities are joint book-running managers."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":126409,"accession_number":"0001847903-25-000154","cik":1847903,"company_name":"Centessa Pharmaceuticals plc","ticker":"CNTA","form_type":"8-K","filed_at":"2025-11-05T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Centessa reports Q3 net loss of $54.9M; ORX750 Phase 2a meets endpoints in NT1, NT2, IH","event_type":"earnings","confidence":"high","bullets":["Net loss of $54.9M in Q3 2025 vs $42.6M in Q3 2024; R&D expenses rose to $41.6M.","Cash and investments $349M as of Sep 30, 2025, expected to fund operations into mid-2027.","ORX750 Phase 2a showed statistically significant improvements on MWT, ESS, and cataplexy rate across NT1, NT2, and IH at low doses.","ORX142 Phase 1 demonstrated rapid onset and differentiated PK; patient studies planned for Q1 2026.","Registrational program for ORX750 expected to start Q1 2026; ORX489 IND-enabling studies ongoing."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.98,"consensus_revenue_estimate":null,"consensus_revenue_actual":15000000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":143169,"accession_number":"0001847903-25-000133","cik":1847903,"company_name":"Centessa Pharmaceuticals plc","ticker":"CNTA","form_type":"8-K","filed_at":"2025-08-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Centessa Q2 net loss $50.3M; cash $404.1M; ORX750 Phase 2a data on track for 2025","event_type":"earnings","confidence":"high","bullets":["Net loss of $50.3M for Q2 2025, up from $43.8M in Q2 2024; R&D expenses rose to $42.7M.","Cash, cash equivalents and investments totaled $404.1M as of June 30, 2025, expected to fund into mid-2027.","ORX750 Phase 2a CRYSTAL-1 study ongoing; data in NT1, NT2, and idiopathic hypersomnia expected in 2025.","ORX142 Phase 1 first-in-human trial initiated; data in sleep-deprived healthy volunteers expected in 2025.","ORX489 in IND-enabling studies for neuropsychiatric disorders."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.57,"consensus_revenue_estimate":null,"consensus_revenue_actual":15000000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":161298,"accession_number":"0001847903-25-000093","cik":1847903,"company_name":"Centessa Pharmaceuticals plc","ticker":"CNTA","form_type":"8-K","filed_at":"2025-06-20T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Centessa shareholders approve all proposals at 2025 AGM, including director re-elections","event_type":"other_material","confidence":"high","bullets":["Re-elected Arjun Goyal with 116.9M votes for, 463,793 against; Samarth Kulkarni with 97.7M for, 19.6M against.","Approved KPMG LLP as UK statutory auditors and KPMG LLP (Delaware) as independent auditor for FY2025.","Adopted UK statutory accounts for FY2024; no dividend recommended.","Authorized directors to allot shares up to £133,184 nominal value under Companies Act.","Special resolution passed to empower board to allot equity for cash without pre-emption rights."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":161297,"accession_number":"0001847903-25-000090","cik":1847903,"company_name":"Centessa Pharmaceuticals plc","ticker":"CNTA","form_type":"8-K","filed_at":"2025-06-17T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"FDA clears IND for Centessa's ORX142, Phase 1 study in sleep-deprived volunteers planned","event_type":"regulatory","confidence":"high","bullets":["FDA cleared IND for ORX142, a novel OX2R agonist for neurological/neurodegenerative disorders.","Phase 1 study will evaluate safety, PK, and PD (MWT, KSS) in acutely sleep-deprived healthy adults.","Clinical data from Phase 1 expected this year; study initiation imminent.","ORX142 is second orexin franchise candidate; ORX750 in Phase 2a for narcolepsy/IH."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.55,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":161296,"accession_number":"0001847903-25-000081","cik":1847903,"company_name":"Centessa Pharmaceuticals plc","ticker":"CNTA","form_type":"8-K","filed_at":"2025-05-29T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Centessa appoints Raphael Deferiere as Chief Accounting Officer","event_type":"leadership","confidence":"high","bullets":["Raphael Deferiere, CPA, appointed CAO effective May 27, 2025; John Crowley remains CFO.","Base salary of $400,000; annual bonus target 35% of base; option for 165,000 ADSs.","Option vests 25% at one year, then 36 equal monthly installments.","Mr. Deferiere was an Assurance Partner at Ernst & Young LLP (July 2017 – May 2025)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}